Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.050
-0.200 (-4.71%)
At close: Apr 28, 2026, 4:00 PM EDT
4.070
+0.020 (0.49%)
After-hours: Apr 28, 2026, 6:44 PM EDT
Zentalis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Zentalis Pharmaceuticals stock have an average target of 6.60, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 62.96% from the current stock price of 4.05.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zentalis Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $6 → $10 | Strong Buy | Maintains | $6 → $10 | +146.91% | Apr 10, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +48.15% | Mar 27, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $4 | Hold | Maintains | $8 → $4 | -1.23% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +23.46% | Aug 7, 2025 |
| Wedbush | Wedbush | Hold Reiterates $4 | Hold | Reiterates | $4 | -1.23% | May 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
22.23M
EPS This Year
-1.94
from -1.91
EPS Next Year
-1.66
from -1.94
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 47.5M | ||||||
| Avg | n/a | 22.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.33 | -0.85 | ||||||
| Avg | -1.94 | -1.66 | ||||||
| Low | -2.30 | -2.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.